EMA/297553/2024

European Medicines Agency decision

P/0243/2024

of 19 July 2024

on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / lamivudine (Dovato), (EMEA-001940-PIP01-16-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0243/2024

of 19 July 2024

on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / lamivudine (Dovato), (EMEA-001940-PIP01-16-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0074/2017 issued on 17 March 2017, the decision P/0151/2018 issued on 18 May 2018, the decision P/0319/2019 issued on 11 September 2019, the decision P/0372/2020 issued on 9 September 2020, and the decision P/0391/2022 issued on 9 September 2022 and the decision P/0121/2023 issued on 14 April 2023,

Having regard to the application submitted by ViiV Healthcare UK Limited on 26 February 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 May 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for dolutegravir / lamivudine (Dovato), film-coated tablet, dispersible tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to ViiV Healthcare UK Limited, 980 Great West Road, TW8 9GS - Brentford, Middlesex, United Kingdom.

EMA/PDCO/108979/2024
Amsterdam, 31 May 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001940-PIP01-16-M06

Scope of the application

Active substance(s):

Dolutegravir / lamivudine

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of human immunodeficiency virus type 1 (HIV-1) infection

Pharmaceutical form(s):

Film-coated tablet

Dispersible tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

ViiV Healthcare UK Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, ViiV Healthcare UK Limited submitted to the European Medicines Agency on 26 February 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0074/2017 issued on 17 March 2017, the decision P/0151/2018 issued on 18 May 2018, the decision P/0319/2019 issued on 11 September 2019, the decision P/0372/2020 issued on 9 September 2020, and the decision P/0391/2022 issued on 9 September 2022 and the decision P/0121/2023 issued on 14 April 2023.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 2 April 2024.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
    - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.
2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of human immunodeficiency virus type 1 (HIV-1) infection

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- film-coated tablet, dispersible tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of human immunodeficiency virus type 1 (HIV-1) infection

2.1.1. Indication(s) targeted by the PIP

- Lamivudine (3TC) / dolutegravir (DTG) fix-dose-combination (FDC) is to be indicated for use as a 2-drug complete regimen for the treatment of ART-naïve adolescents above 12 to less than 18 years of age with plasma HIV-1 RNA less than 500,000 c/mL, or virologically suppressed adolescents, and without known viral drug resistance to either agent.
- DTG/3TC FDC is to be indicated for use as a 2-drug complete regimen for the treatment of HIV-1 infection in paediatric subjects aged at least 2 years and older and weighing less than 40 adults, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Dispersible tablet

2.1.4. Measures

Area	**Description**
Quality-related studies	**Study 1** Paediatric formulation development.
Non-clinical studies	Not applicable.

Clinical studies	**Study 2** Single dose, crossover, relative bioavailability study of DTG plus 3TC paediatric formulation as compared to approved DTG and 3TC formulations. **Study 3** Open-label, single-arm study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of the fixed-dose combination of DTG/3TC in virologically-suppressed HIV-1 infected paediatric subjects aged at least 2 years and weighing less than 40 kg of body weight (207742).
Extrapolation, modelling and simulation studies	**Study 4** Extrapolation of efficacy from adult to adolescents 12 years to less than 18 years old weighing at least 40 kg. **Study 5** Modelling and Simulation study to confirm dose and the extrapolation of use of the DTG/3TC FDC in antiretroviral-naïve children infected with HIV-1 from 2 years to less than 12 years of age and weighing between 10 kg to less than 40 kg. **Study 6** Extrapolation of efficacy from adult to paediatric subjects aged at least 2 years and weighing less than 40 kg.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s):

1. Treatment of HIV-1

Authorised indication(s):

- Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
  - Invented name(s): Dovato
  - Authorised pharmaceutical form(s): Film-coated tablet
  - Authorised route(s) of administration: Oral use
  - Authorised via centralised procedure